New strategies for Alzheimer disease and cognitive impairment

Oxidative Medicine and Cellular Longevity

Volumn 2, Issue 5, 2009, Pages 279-289

  Maiese, Kenneth ^a,b,c,d   Chong, Zhao Zhong ^a   Hou, Jinling ^a   Shang, Yan Chen ^a  

^a Division of Cellular and Molecular Cerebral Ischemia   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c KARMANOS CANCER INSTITUTE   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aging; Alzheimer disease; Angiogenesis; Apoptosis; Cognitive loss; Diabetes; Erythropoietin; Forkhead transcription factors; Immune system; Ischemia; Neurodegeneration; Oxidative stress; Vascular disease; Wingless; Wnt

Indexed keywords

BIOLOGICAL MARKER; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; FORKHEAD TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXO;

ALZHEIMER DISEASE; ARTHRITIS; BRAIN METABOLISM; COGNITIVE DEFECT; DISEASE COURSE; GLAUCOMA; HEART FAILURE; HUMAN; NEOVASCULARIZATION (PATHOLOGY); NERVOUS SYSTEM; NONHUMAN; RETINA DEGENERATION; REVIEW; SURVIVAL; ULCER;

ALZHEIMER DISEASE; COGNITION DISORDERS; ERYTHROPOIETIN; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; NERVOUS SYSTEM; REACTIVE OXYGEN SPECIES;

EID: 76749087751     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.4161/oxim.2.5.9990     Document Type: Review

References (255)

1. Mendiondo MS, Kryscio RJ, Schmitt FA. Models of progression in AD: predicting disability and costs. Neurology 2001; 57:943-4.
2. McCormick WC, Hardy J, Kukull WA, Bowen JD, Teri L, Zitzer S, et al. Healthcare utilization and costs in managed care patients with Alzheimer's disease during the last few years of life. J Am Geriatr Soc 2001; 49:1156-60.
3. Chong ZZ, Li F, Maiese K. Oxidative stress in the brain: Novel cellular targets that govern survival during neurodegenerative disease. Prog Neurobiol 2005; 75:207-46.
4. Maiese K. Triple play: Promoting neurovascular longevity with nicotinamide, WNT and erythropoietin in diabetes mellitus. Biomed Pharmacother 2008; 62:218-32.
5. Maiese K, Chong ZZ, Hou J, Shang YC. Erythropoietin and oxidative stress. Curr Neurovasc Res 2008; 5:125-42.
6. Regulska M, Leskiewicz M, Budziszewska B, Kutner A, Jantas D, Basta-Kaim A, et al. Inhibitory effects of 1,25-dihydroxyvitamin D(3) and its low-calcemic analogues on staurosporine-induced apoptosis. Pharmacol Rep 2007; 59:393-401.
7. Chlopicki S, Swies J, Mogielnicki A, Buczko W, Bartus M, Lomnicka M, et al. 1-Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti-thrombotic activity mediated by a cyclooxygenase-2/prostacyclin pathway. Br J Pharmacol 2007; 152:230-9.
8. Chong ZZ, Lin SH, Maiese K. Nicotinamide Modulates Mitochondrial Membrane Potential and Cysteine Protease Activity during Cerebral Vascular Endothelial Cell Injury. J Vasc Res 2002; 39:131-47.
9. Feng Y, Paul IA, LeBlanc MH. Nicotinamide reduces hypoxic ischemic brain injury in the newborn rat. Brain Res Bull 2006; 69:117-22.
10. Hara N, Yamada K, Shibata T, Osago H, Hashimoto T, Tsuchiya M. Elevation of cellular NAD levels by nicotinic acid and involvement of nicotinic acid phosphoribosyltransferase in human cells. J Biol Chem 2007; 282:24574-82.
11. Ieraci A, Herrera DG. Nicotinamide Protects against Ethanol-Induced Apoptotic Neurodegeneration in the Developing Mouse Brain. PLoS Med 2006; 3:101.
12. Lin SH, Vincent A, Shaw T, Maynard KI, Maiese K. Prevention of nitric oxide-induced neuronal injury through the modulation of independent pathways of programmed cell death. J Cereb Blood Flow Metab 2000; 20:1380-91.
13. Maiese K, Chong ZZ. Nicotinamide: necessary nutrient emerges as a novel cytoprotectant for the brain. Trends Pharmacol Sci 2003; 24:228-32.
14. Chong ZZ, Li F, Maiese K. Attempted Cell Cycle Induction in Post-Mitotic Neurons Occurs in Early and Late Apoptotic Programs Through Rb, E2F1 and Caspase 3. Curr Neurovasc Res 2006; 3:25-39.
15. De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST, et al. Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 2007; 282:11590-601.
16. Lin SH, Maiese K. The metabotropic glutamate receptor system protects against ischemic free radical programmed cell death in rat brain endothelial cells. J Cereb Blood Flow Metab 2001; 21:262-75.
17. He XL, Wang YH, Gao M, Li XX, Zhang TT, Du GH. Baicalein protects rat brain mitochondria against chronic cerebral hypoperfusion-induced oxidative damage. Brain Res 2009; 1249:212-21.
18. Maiese K, Chong ZZ, Shang YC, Hou J. Therapeutic promise and principles: Metabotropic glutamate receptors. Oxid Med Cell Longev 2008; 1:1-14.
19. Plecita-Hlavata L, Lessard M, Santorova J, Bewersdorf J, Jezek P. Mitochondrial oxidative phosphorylation and energetic status are reflected by morphology of mitochondrial network in INS-1E and HEP-G2 cells viewed by 4Pi microscopy. Biochim Biophys Acta 2008; 1777:834-46.
20. Chong ZZ, Li F, Maiese K. Stress in the brain: novel cellular mechanisms of injury linked to Alzheimer's disease. Brain Res Brain Res Rev 2005; 49:1-21. (Pubitemid 40800161)
21. Harris SE, Fox H, Wright AF, Hayward C, Starr JM, Whalley LJ, et al. A genetic association analysis of cognitive ability and cognitive ageing using 325 markers for 109 genes associated with oxidative stress or cognition. BMC Genet 2007; 8:43.
22. Leuner K, Hauptmann S, Abdel-Kader R, Scherping I, Keil U, Strosznajder JB, et al. Mitochondrial dysfunction: the first domino in brain aging and Alzheimer's disease? Antioxid Redox Signal 2007; 9:1659-75.
23. Okouchi M, Ekshyyan O, Maracine M, Aw TY. Neuronal apoptosis in neurodegeneration. Antioxid Redox Signal 2007; 9:1059-96.
24. Chong ZZ, Kang JQ, Maiese K. Akt1 drives endothelial cell membrane asymmetry and microglial activation through Bcl-x(L) and caspase 1, 3 and 9. Exp Cell Res 2004; 296:196-207.
25. Chong ZZ, Li F, Maiese K. The pro-survival pathways of mTOR and protein kinase B target glycogen synthase kinase-3beta and nuclear factor-kappaB to foster endogenous microglial cell protection. Int J Mol Med 2007; 19:263-72.
26. Kang JQ, Chong ZZ, Maiese K. Critical role for Akt1 in the modulation of apoptotic phosphatidylserine exposure and microglial activation. Mol Pharmacol 2003; 64:557-69.
27. Karunakaran S, Diwakar L, Saeed U, Agarwal V, Ramakrishnan S, Iyengar S, et al. Activation of apoptosis signal regulating kinase 1 (ASK1) and translocation of death-associated protein, Daxx, in substantia nigra pars compacta in a mouse model of Parkinson's disease: protection by alpha-lipoic acid. Faseb J 2007; 21:2226-36.
28. Verdaguer E, Susana Gde A, Clemens A, Pallas M, Camins A. Implication of the transcription factor E2F-1 in the modulation of neuronal apoptosis. Biomed Pharmacother 2007; 61:390-9.
29. Chong ZZ, Li F, Maiese K. Employing new cellular therapeutic targets for Alzheimer's disease: a change for the better? Curr Neurovasc Res 2005; 2:55-72.
30. Maiese K, Chong ZZ, Shang YC, Hou J. Rogue proliferation versus restorative protection: where do we draw the line for Wnt and forkhead signaling? Expert opinion on therapeutic targets 2008; 12:905-16.
31. Maiese K, Vincent A, Lin SH, Shaw T. Group I and Group III metabotropic glutamate receptor subtypes provide enhanced neuroprotection. J Neurosci Res 2000; 62:257-72.
32. Mari C, Karabiyikoglu M, Goris ML, Tait JF, Yenari MA, Blankenberg FG. Detection of focal hypoxicischemic injury and neuronal stress in a rodent model of unilateral MCA occlusion/reperfusion using radiolabeled annexin V. Eur J Nucl Med Mol Imaging 2004; 31:733-9.
33. Chong ZZ, Kang J, Li F, Maiese K. mGluRI Targets Microglial Activation and Selectively Prevents Neuronal Cell Engulfment Through Akt and Caspase Dependent Pathways. Curr Neurovasc Res 2005; 2:197-211.
34. Li F, Chong ZZ, Maiese K. Microglial integrity is maintained by erythropoietin through integration of Akt and its substrates of glycogen synthase kinase-3beta, beta-catenin and nuclear factor-kappaB. Curr Neurovasc Res 2006; 3:187-201.
35. Chong ZZ, Kang JQ, Maiese K. Metabotropic glutamate receptors promote neuronal and vascular plasticity through novel intracellular pathways. Histol Histopathol 2003; 18:173-89.
36. Kang JQ, Chong ZZ, Maiese K. Akt1 protects against inflammatory microglial activation through maintenance of membrane asymmetry and modulation of cysteine protease activity. J Neurosci Res 2003; 74:37-51.
37. Mallat M, Marin-Teva JL, Cheret C. Phagocytosis in the developing CNS: more than clearing the corpses. Curr Opin Neurobiol 2005; 15:101-7.
38. Li F, Chong ZZ, Maiese K. Cell Life Versus Cell Longevity: The Mysteries Surrounding the NAD(+) Precursor Nicotinamide. Curr Med Chem 2006; 13:883-95.
39. Li F, Chong ZZ, Maiese K. Winding through the WNT pathway during cellular development and demise. Histol Histopathol 2006; 21:103-24.
40. Chong ZZ, Kang JQ, Maiese K. Erythropoietin fosters both intrinsic and extrinsic neuronal protection through modulation of microglia, Akt1, Bad and caspase-mediated pathways. Br J Pharmacol 2003; 138:1107-18.
41. Lin SH, Chong ZZ, Maiese K. Cell cycle induction in post-mitotic neurons proceeds in concert with the initial phase of programmed cell death in rat. Neurosci Lett 2001; 310:173-7.
42. Maiese K. The dynamics of cellular injury: transformation into neuronal and vascular protection. Histol Histopathol 2001; 16:633-44.
43. Maiese K, Ahmad I, TenBroeke M, Gallant J. Metabotropic glutamate receptor subtypes independently modulate neuronal intracellular calcium. J Neurosci Res 1999; 55:472-85.
44. Vincent AM, Maiese K. Direct temporal analysis of apoptosis induction in living adherent neurons. J Histochem Cytochem 1999; 47:661-72.
45. Chong ZZ, Li F, Maiese K. Cellular demise and inf lammatory microglial activation during betaamyloid toxicity are governed by Wnt1 and canonical signaling pathways. Cell Signal 2007; 19:1150-62.
46. Shang YC, Chong ZZ, Hou J, Maiese K. The forkhead transcription factor FoxO3a controls microglial inflammatory activation and eventual apoptotic injury through caspase 3. Curr Neurovasc Res 2009; 6:20-31.
47. Chong ZZ, Lin SH, Kang JQ, Maiese K. Erythropoietin prevents early and late neuronal demise through modulation of Akt1 and induction of caspase 1, 3 and 8. J Neurosci Res 2003; 71:659-69.
48. Chong ZZ, Lin SH, Kang JQ, Maiese K. The tyrosine phosphatase SHP2 modulates MAP kinase p38 and caspase 1 and 3 to foster neuronal survival. Cell Mol Neurobiol 2003; 23:561-78.
49. Maiese K, Boccone L. Neuroprotection by peptide growth factors against anoxia and nitric oxide toxicity requires modulation of protein kinase C. J Cereb Blood Flow Metab 1995; 15:440-9.
50. Maiese K, Boniece IR, Skurat K, Wagner JA. Protein kinases modulate the sensitivity of hippocampal neurons to nitric oxide toxicity and anoxia. J Neurosci Res 1993; 36:77-87.
51. Maiese K, TenBroeke M, Kue I. Neuroprotection of lubeluzole is mediated through the signal transduction pathways of nitric oxide. J Neurochem 1997; 68:710-4.
52. Salinas M, Diaz R, Abraham NG, Ruiz de Galarreta CM, Cuadrado A. Nerve growth factor protects against 6-hydroxydopamine-induced oxidative stress by increasing expression of heme oxygenase-1 in a phosphatidylinositol 3-kinase-dependent manner. J Biol Chem 2003; 278:13898-904.
53. Leytin V, Allen DJ, Mykhaylov S, Lyubimov E, Freedman J. Thrombin-triggered platelet apoptosis. J Thromb Haemost 2006; 4:2656-63.
54. Maiese K, Vincent AM. Critical temporal modulation of neuronal programmed cell injury. Cell Mol Neurobiol 2000; 20:383-400.
55. Maiese K, Vincent AM. Membrane asymmetry and DNA degradation: functionally distinct determinants of neuronal programmed cell death. J Neurosci Res 2000; 59:568-80.
56. Chong ZZ, Kang JQ, Maiese K. Essential cellular regulatory elements of oxidative stress in early and late phases of apoptosis in the central nervous system. Antioxid Redox Signal 2004; 6:277-87.
57. Dombroski D, Balasubramanian K, Schroit AJ. Phosphatidylserine expression on cell surfaces promotes antibody-dependent aggregation and thrombosis in beta2-glycoprotein Iimmune mice. J Autoimmun 2000; 14:221-9.
58. Jessel R, Haertel S, Socaciu C, Tykhonova S, Diehl HA. Kinetics of apoptotic markers in exogeneously induced apoptosis of EL4 cells. J Cell Mol Med 2002; 6:82-92.
59. Chong ZZ, Maiese K. The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation and injury. Histol Histopathol 2007; 22:1251-67.
60. Vincent AM, Maiese K. Nitric oxide induction of neuronal endonuclease activity in programmed cell death. Exp Cell Res 1999; 246:290-300. (Pubitemid 29393990)
61. Vincent AM, TenBroeke M, Maiese K. Metabotropic glutamate receptors prevent programmed cell death through the modulation of neuronal endonuclease activity and intracellular pH. Exp Neurol 1999; 155:79-94.
62. +and is a causative event in the death of myocytes in postischemic reperfusion of the heart. J Biol Chem 2001; 276:2571-5.
63. L, Cytochrome c and Caspase-9 Form the Critical Elements for Cerebral Vascular Protection by Erythropoietin. J Cereb Blood Flow Metab 2003; 23:320-30.
64. Chong ZZ, Lin SH, Li F, Maiese K. The sirtuin inhibitor nicotinamide enhances neuronal cell survival during acute anoxic injury through Akt, Bad, PARP and mitochondrial associated "anti-apoptotic" pathways. Curr Neurovasc Res 2005; 2:271-85.
65. Maiese K, Chong ZZ. Insights into oxidative stress and potential novel therapeutic targets for Alzheimer disease. Restor Neurol Neurosci 2004; 22:87-104.
66. +precursor and nutrient nicotinamide. Front Biosci 2004; 9:2500-20.
67. Wilson FH, Hariri A, Farhi A, Zhao H, Petersen KF, Toka HR, et al. A cluster of metabolic defects caused by mutation in a mitochondrial tRNA. Science 2004; 306:1190-4.
68. Roberts E Jr, Chih CP. The influence of age of pH regulation in hippocampal slices before, during and after anoxia. J Cereb Blood Flow Metab 1997; 17:560-6.
69. Cardella F. Insulin therapy during diabetic ketoacidosis in children. Acta Biomed 2005; 76:49-54.
70. Kratzsch J, Knerr I, Galler A, Kapellen T, Raile K, Korner A, et al. Metabolic decompensation in children with type 1 diabetes mellitus associated with increased serum levels of the soluble leptin receptor. Eur J Endocrinol 2006; 155:609-14.
71. Ito N, Bartunek J, Spitzer KW, Lorell BH. Effects of the nitric oxide donor sodium nitroprusside on intracellular pH and contraction in hypertrophied myocytes. Circulation 1997; 95:2303-11.
72. Vincent AM, TenBroeke M, Maiese K. Neuronal intracellular pH directly mediates nitric oxideinduced programmed cell death. J Neurobiol 1999; 40:171-84.
73. Maiese K, Li F, Chong ZZ. Erythropoietin in the brain: can the promise to protect be fulfilled? Trends Pharmacol Sci 2004; 25:577-83.
74. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA 2005; 293:90-5.
75. Fliser D, Haller H. Erythropoietin and treatment of non-anemic conditions-cardiovascular protection. Semin Hematol 2007; 44:212-7.
76. Teramo KA, Widness JA. Increased fetal plasma and amniotic fluid erythropoietin concentrations: markers of intrauterine hypoxia. Neonatology 2009; 95:105-16.
77. Maiese K. Marking the onset of oxidative stress: Biomarkers and novel strategies. Oxid Med Cell Longev 2009; 2:1.
78. Maiese K, Chong ZZ, Li F, Shang YC. Erythropoietin: Elucidating new cellular targets that broaden therapeutic strategies. Prog Neurobiol 2008; 85:194-213.
79. Maiese K, Chong ZZ, Shang YC. Raves and risks for erythropoietin. Cytokine Growth Factor Rev 2008; 19:145-55.
80. Chong ZZ, Kang JQ, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 2002; 106:2973-9.
81. Chong ZZ, Maiese K. Erythropoietin involves the phosphatidylinositol 3-kinase pathway, 14-3-3 protein and FOXO3a nuclear trafficking to preserve endothelial cell integrity. Br J Pharmacol 2007; 150:839-50.
82. Mikati MA, Hokayem JA, Sabban ME. Effects of a single dose of erythropoietin on subsequent seizure susceptibility in rats exposed to acute hypoxia at p10. Epilepsia 2007; 48:175-81.
83. Moon C, Krawczyk M, Paik D, Coleman T, Brines M, Juhaszova M, et al. Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties. J Pharmacol Exp Ther 2006; 316:999-1005.
84. Um M, Gross AW, Lodish HF. A "classical" homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SHSY5Y and pheochromocytoma PC-12 cells. Cell Signal 2007; 19:634-45.
85. Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol 2008; 141:14-31.
86. Schumann C, Triantafilou K, Krueger S, Hombach V, Triantafilou M, Becher G, et al. Detection of erythropoietin in exhaled breath condensate of nonhypoxic subjects using a multiplex bead array. Mediators Inflamm 2006; 2006:18061.
87. Kaindl AM, Sifringer M, Koppelstaetter A, Genz K, Loeber R, Boerner C, et al. Erythropoietin protects the developing brain from hyperoxia-induced cell death and proteome changes. Ann Neurol 2008; 64:523-34.
88. Yis U, Kurul SH, Kumral A, Tugyan K, Cilaker S, Yilmaz O, et al. Effect of erythropoietin on oxygeninduced brain injury in the newborn rat. Neurosci Lett 2008; 448:245-9.
89. He Z, Huang L, Wu Y, Wang J, Wang H, Guo L. DDPH: improving cognitive deficits beyond its alpha1-adrenoceptor antagonism in chronic cerebral hypoperfused rats. Eur J Pharmacol 2008; 588:178-88.
90. Berkingali N, Warnecke A, Gomes P, Paasche G, Tack J, Lenarz T, et al. Neurite outgrowth on cultured spiral ganglion neurons induced by erythropoietin. Hear Res 2008; 243:121-6.
91. Shah RC, Wilson RS, Tang Y, Dong X, Murray A, Bennett DA. Relation of hemoglobin to level of cognitive function in older persons. Neuroepidemiology 2009; 32:40-6.
92. Bierer R, Peceny MC, Hartenberger CH, Ohls RK. Erythropoietin concentrations and neurodevelopmental outcome in preterm infants. Pediatrics 2006; 118:635-40.
93. Pillai A, Dhandapani KM, Pillai BA, Terry AV Jr, Mahadik SP. Erythropoietin prevents haloperidol treatment-induced neuronal apoptosis through regulation of BDNF. Neuropsychopharmacology 2008; 33:1942-51.
94. Assaraf MI, Diaz Z, Liberman A, Miller WH Jr, Arvanitakis Z, Li Y, et al. Brain erythropoietin receptor expression in Alzheimer disease and mild cognitive impairment. J Neuropathol Exp Neurol 2007; 66:389-98.
95. Palazzuoli A, Silverberg D, Iovine F, Capobianco S, Giannotti G, Calabro A, et al. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-typenatriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 2006; 152:1096-9.
96. Gleissner CA, Klingenberg R, Staritz P, Koch A, Ehlermann P, Wiggenhauser A, et al. Role of erythropoietin in anemia after heart transplantation. Int J Cardiol 2006; 112:341-7.
97. Mocini D, Leone T, Tubaro M, Santini M, Penco M. Structure, production and function of erythropoietin: implications for therapeutical use in cardiovascular disease. Curr Med Chem 2007; 14:2278-87.
98. Digicaylioglu M, Garden G, Timberlake S, Fletcher L, Lipton SA. Acute neuroprotective synergy of erythropoietin and insulin-like growth factor I. Proc Natl Acad Sci USA 2004; 101:9855-60.
99. Genc S, Koroglu TF, Genc K. Erythropoietin as a novel neuroprotectant. Restor Neurol Neurosci 2004; 22:105-19.
100. Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N, et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 1994; 91:3974-8.
101. Ogilvie M, Yu X, Nicolas-Metral V, Pulido SM, Liu C, Ruegg UT, et al. Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts. J Biol Chem 2000; 275:39754-61.
102. Fenjves ES, Ochoa MS, Cabrera O, Mendez AJ, Kenyon NS, Inverardi L, et al. Human, nonhuman primate and rat pancreatic islets express erythropoietin receptors. Transplantation 2003; 75:1356-60.
103. Chong ZZ, Kang JQ, Maiese K. Erythropoietin: cytoprotection in vascular and neuronal cells. Curr Drug Targets Cardiovasc Haematol Disord 2003; 3:141-54.
104. Yamaji R, Okada T, Moriya M, Naito M, Tsuruo T, Miyatake K, et al. Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA. Eur J Biochem 1996; 239:494-500.
105. Maiese K, Chong Z, Li F. Reducing oxidative stress and enhancing neurovascular longevity during diabetes mellitus. In: Neurovascular Medicine: Pursuing Cellular Longevity for Healthy Aging Maiese K, Ed, Oxford University Press: New York, NY 2009; 540-64.
106. Chong ZZ, Kang JQ, Maiese K. Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades. J Cereb Blood Flow Metab 2002; 22:503-14.
107. Obara N, Imagawa S, Nakano Y, Suzuki N, Yamamoto M, Nagasawa T. Suppression of erythropoietin gene expression by cadmium depends on inhibition of HIF-1, not stimulation of GATA-2. Arch Toxicol 2003; 77:267-73.
108. Li CL, Jiang J, Fan YQ, Fu GS, Wang JA, Fan WM. Knockout of the tumor necrosis factor a receptor 1 gene can upregulate erythropoietin receptor during myocardial ischemiareperfusion injury in mice. Chin Med J (Engl) 2009; 122:566-70.
109. Nagai A, Nakagawa E, Choi HB, Hatori K, Kobayashi S, Kim SU. Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia and oligodendrocytes grown in culture. J Neuropathol Exp Neurol 2001; 60:386-92.
110. Pregi N, Wenker S, Vittori D, Leiros CP, Nesse A. TNFalpha-induced apoptosis is prevented by erythropoietin treatment on SH-SY5Y cells. Exp Cell Res 2009; 315:419-31.
111. Maiese K, Chong ZZ, Shang YC, Hou J. A "FOXO" in sight: targeting Foxo proteins from conception to cancer. Med Res Rev 2009; 29:395-418.
112. Weigel D, Jurgens G, Kuttner F, Seifert E, Jackle H. The homeotic gene fork head encodes a nuclear protein and is expressed in the terminal regions of the Drosophila embryo. Cell 1989; 57:645-58.
113. Maiese K, Chong ZZ, Shang YC. "Sly as a FOXO": New paths with Forkhead signaling in the brain. Curr Neurovasc Res 2007; 4:295-302.
114. Kaestner KH, Knochel W, Martinez DE. Unified nomenclature for the winged helix/forkhead transcription factors. Genes Dev 2000; 14:142-6.
115. Maiese K, Chong ZZ, Shang YC. OutFOXOing disease and disability: the therapeutic potential of targeting FoxO proteins. Trends Mol Med 2008; 14:219-27.
116. Maiese K, Chong ZZ, Shang YC, Hou J. FoxO proteins: cunning concepts and considerations for the cardiovascular system. Clin Sci (Lond) 2009; 116:191-203.
117. Maiese K, Li F, Chong ZZ. Erythropoietin and cancer. JAMA 2005; 293:1858-9.
118. Bloomer R, Fisher-Wellman K. Systemic oxidative stress is increased to a greater degree in young, obese women following consumption of a high fat meal. Oxid Med Cell Longev 2009; 2:19-25.
119. Fisher-Wellman K, Bell H, Bloomer R. Oxidative stress and antioxidant defense mechanisms linked to exercise during cardiopulmonary and metabolic disorders. Oxid Med Cell Longev 2009; 2:43-51.
120. Castrillon DH, Miao L, Kollipara R, Horner JW, DePinho RA. Suppression of ovarian follicle activation in mice by the transcription factor Foxo3a. Science 2003; 301:215-8.
121. Furuyama T, Nakazawa T, Nakano I, Mori N. Identification of the differential distribution patterns of mRNAs and consensus binding sequences for mouse DAF-16 homologues. Biochem J 2000; 349:629-34.
122. Furuyama T, Yamashita H, Kitayama K, Higami Y, Shimokawa I, Mori N. Effects of aging and caloric restriction on the gene expression of Foxo1, 3 and 4 (FKHR, FKHRL1 and AFX) in the rat skeletal muscles. Microsc Res Tech 2002; 59:331-4.
123. Hoekman MF, Jacobs FM, Smidt MP, Burbach JP. Spatial and temporal expression of FoxO transcription factors in the developing and adult murine brain. Gene Expr Patterns 2006; 6:134-40.
124. Lappas M, Lim R, Riley C, Rice GE, Permezel M. Localisation and expression of FoxO1 proteins in human gestational tissues. Placenta 2009; 30:256-62.
125. Maiese K, Chong Z, Hou J, Shang Y. The "O" Class: Crafting clinical care with FoxO transcription factors. In: Forkhead Transcription Factors: Vital Elements in Biology and Medicine Maiese K, Ed., Landes Bioscience, Austin, TX 2009; 665.
126. Maiese K, Chong ZZ, Shang YC, Hou J. Clever cancer strategies with FoxO transcription factors. Cell Cycle 2008; 7:3829-39.
127. Modur V, Nagarajan R, Evers BM, Milbrandt J. FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J Biol Chem 2002; 277:47928-37.
128. Matsuzaki H, Daitoku H, Hatta M, Tanaka K, Fukamizu A. Insulin-induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation. Proc Natl Acad Sci USA 2003; 100:11285-90.
129. Plas DR, Thompson CB. Akt activation promotes degradation of tuberin and FOXO3a via the proteasome. J Biol Chem 2003; 278:12361-6.
130. Jagani Z, Singh A, Khosravi-Far R. FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis. Biochim Biophys Acta 2008; 1785:63-84.
131. van der Horst A, Burgering BM. Stressing the role of FoxO proteins in lifespan and disease. Nat Rev Mol Cell Biol 2007; 8:440-50.
132. Song M, Park JE, Park SG, Lee do H, Choi HK, Park BC, et al. NSC-87877, inhibitor of SHP-1/2 PTPs, inhibits dual-specificity phosphatase 26 (DUSP26). Biochem Biophys Res Commun 2009; 381:491-5.
133. Chong ZZ, Li F, Maiese K. Activating Akt and the brain's resources to drive cellular survival and prevent inflammatory injury. Histol Histopathol 2005; 20:299-315.
134. Gayer CP, Chaturvedi LS, Wang S, Craig DH, Flanigan T, Basson MD. Strain-induced proliferation requires the phosphatidylinositol 3-kinase/AKT/glycogen synthase kinase pathway. J Biol Chem 2009; 284:2001-11.
135. An J, Zhang C, Polavarapu R, Zhang X, Yepes M. Tissue-type plasminogen activator and the lowdensity lipoprotein receptor-related protein induce Akt phosphorylation in the ischemic brain. Blood 2008; 112:2787-94.
136. Slaets H, Dumont D, Vanderlocht J, Noben JP, Leprince P, Robben J, et al. Leukemia inhibitory factor induces an antiapoptotic response in oligodendrocytes through Aktphosphorylation and upregulation of 14-3-3. Proteomics 2008; 8:1237-47.
137. Williams R, Dhillon NK, Hegde ST, Yao H, Peng F, Callen S, et al. Proinflammatory cytokines and HIV-1 synergistically enhance CXCL10 expression in human astrocytes. Glia 2009; 57:734-43.
138. Rodriguez-Blanco J, Martin V, Herrera F, Garcia-Santos G, Antolin I, Rodriguez C. Intracellular signaling pathways involved in post-mitotic dopaminergic PC12 cell death induced by 6-hydroxydopamine. J Neurochem 2008; 107:127-40.
139. Anitha M, Gondha C, Sutliff R, Parsadanian A, Mwangi S, Sitaraman SV, et al. GDNF rescues hyperglycemia-induced diabetic enteric neuropathy through activation of the PI3K/Akt pathway. J Clin Invest 2006; 116:344-56.
140. Burgos-Ramos E, Martos-Moreno GA, Lopez MG, Herranz R, Aguado-Llera D, Egea J, et al. The N-terminal tripeptide of insulin-like growth factor-I protects against beta-amyloidinduced somatostatin depletion by calcium and glycogen synthase kinase 3 beta modulation. J Neurochem 2009; 109:360-70.
141. Burgos-Ramos E, Puebla-Jimenez L, Arilla-Ferreiro E. Minocycline provides protection against betaamyloid( 25-35)-induced alterations of the somatostatin signaling pathway in the rat temporal cortex. Neuroscience 2008; 154:1458-66.
142. Burgos-Ramos E, Puebla-Jimenez L, Arilla-Ferreiro E. Minocycline prevents Abeta(25-35)-induced reduction of somatostatin and neprilysin content in rat temporal cortex. Life Sci 2009; 84:205-10.
143. Chong ZZ, Li F, Maiese K. Erythropoietin requires NFkappaB and its nuclear translocation to prevent early and late apoptotic neuronal injury during betaamyloid toxicity. Curr Neurovasc Res 2005; 2:387-99.
144. Campos-Esparza MR, Sanchez-Gomez MV, Matute C. Molecular mechanisms of neuroprotection by two natural antioxidant polyphenols. Cell Calcium 2009; 45:358-68.
145. Kim KH, Oudit GY, Backx PH. Erythropoietin protects against doxorubicin-induced cardiomyopathy via a phosphatidylinositol 3-kinase-dependent pathway. J Pharmacol Exp Ther 2008; 324:160-9.
146. Tajes M, Yeste-Velasco M, Zhu X, Chou SP, Smith MA, Pallas M, et al. Activation of Akt by lithium: Pro-survival pathways in aging. Mech Ageing Dev 2009.
147. Maiese K, Chong ZZ, Li F. Driving cellular plasticity and survival through the signal transduction pathways of metabotropic glutamate receptors. Curr Neurovasc Res 2005; 2:425-46.
148. Salvesen GS, Riedl SJ. Caspase mechanisms. Adv Exp Med Biol 2008; 615:13-23.
149. Chong ZZ, Li F, Maiese K. Group I Metabotropic Receptor Neuroprotection Requires Akt and Its Substrates that Govern FOXO3a, Bim and beta-Catenin During Oxidative Stress. Curr Neurovasc Res 2006; 3:107-17.
150. +precursor nicotinamide governs neuronal survival during oxidative stress through protein kinase B coupled to FOXO3a and mitochondrial membrane potential. J Cereb Blood Flow Metab 2004; 24:728-43.
151. Obexer P, Geiger K, Ambros PF, Meister B, Ausserlechner MJ. FKHRL1-mediated expression of Noxa and Bim induces apoptosis via the mitochondria in neuroblastoma cells. Cell Death Differ 2007; 14:534-47.
152. Gomez-Gutierrez JG, Souza V, Hao HY, Montes de Oca-Luna R, Dong YB, Zhou HS, et al. Adenovirusmediated gene transfer of FKHRL1 triple mutant efficiently induces apoptosis in melanoma cells. Cancer biology & therapy 2006; 5:875-83.
153. Maiese K, Chong ZZ, Shang YC. Mechanistic insights into diabetes mellitus and oxidative stress. Curr Med Chem 2007; 14:1729-38.
154. Maiese K, Morhan SD, Chong ZZ. Oxidative stress biology and cell injury during type 1 and type 2 diabetes mellitus. Curr Neurovasc Res 2007; 4:63-71. (Pubitemid 46280293)
155. Hao J, Shen W, Tian C, Liu Z, Ren J, Luo C, et al. Mitochondrial nutrients improve immune dysfunction in the type 2 diabetic Goto-Kakizaki rats. J Cell Mol Med 2009; 13:701-11.
156. Kuhad A, Bishnoi M, Tiwari V, Chopra K. Suppression of NFkappabeta signaling pathway by tocotrienol can prevent diabetes associated cognitive deficits. Pharmacol Biochem Behav 2009; 92:251-9.
157. Wu SY, Wang GF, Liu ZQ, Rao JJ, Lu L, Xu W, et al. Effect of geniposide, a hypoglycemic glucoside, on hepatic regulating enzymes in diabetic mice induced by a high-fat diet and streptozotocin. Acta Pharmacol Sin 2009; 30:202-8.
158. Guarnieri G, Zanetti M, Vinci P, Cattin MR, Barazzoni R. Insulin resistance in chronic uremia. J Ren Nutr 2009; 19:20-4.
159. Gossai D, Lau-Cam CA. The effects of taurine, taurine homologs and hypotaurine on cell and membrane antioxidative system alterations caused by type 2 diabetes in rat erythrocytes. Adv Exp Med Biol 2009; 643:359-68.
160. Maiese K. Diabetic stress: new triumphs and challenges to maintain vascular longevity. Expert Rev Cardiovasc Ther 2008; 6:281-4.
161. Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon CP, et al. Diabetes and mortality following acute coronary syndromes. JAMA 2007; 298:765-75.
162. Silverberg DS, Wexler D, Iaina A, Schwartz D. The interaction between heart failure and other heart diseases, renal failure and anemia. Semin Nephrol 2006; 26:296-306.
163. Chong ZZ, Shang YC, Maiese K. Vascular injury during elevated glucose can be mitigated by erythropoietin and Wnt signaling. Curr Neurovasc Res 2007; 4:194-204.
164. Mason-Garcia M, Beckman BS, Brookins JW, Powell JS, Lanham W, Blaisdell S, et al. Development of a new radioimmunoassay for erythropoietin using recombinant erythropoietin. Kidney Int 1990; 38:969-75.
165. Namiuchi S, Kagaya Y, Ohta J, Shiba N, Sugi M, Oikawa M, et al. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol 2005; 45:1406-12.
166. Chattopadhyay M, Walter C, Mata M, Fink DJ. Neuroprotective effect of herpes simplex virus-mediated gene transfer of erythropoietin in hyperglycemic dorsal root ganglion neurons. Brain 2009; 132:879-88.
167. Avasarala JR, Konduru SS. Recombinant erythropoietin downregulates IL-6 and CXCR4 genes in TNFalpha-treated primary cultures of human microvascular endothelial cells: implications for multiple sclerosis. J Mol Neurosci 2005; 25:183-9.
168. Miki T, Miura T, Yano T, Takahashi A, Sakamoto J, Tanno M, et al. Alteration in erythropoietin-induced cardioprotective signaling by postinfarct ventricular remodeling. J Pharmacol Exp Ther 2006; 317:68-75.
169. Espada J, Calvo MB, Diaz-Prado S, Medina V. Wnt signalling and cancer stem cells. Clin Transl Oncol 2009; 11:411-27.
170. Wilusz M, Majka M. Role of the Wnt/beta-catenin network in regulating hematopoiesis. Arch Immunol Ther Exp (Warsz) 2008; 56:257-66.
171. Maiese K, Li F, Chong ZZ, Shang YC. The Wnt signaling pathway: Aging gracefully as a protectionist? Pharmacol Ther 2008; 118:58-81.
172. Kikuchi A, Yamamoto H, Sato A. Selective activation mechanisms of Wnt signaling pathways. Trends Cell Biol 2009; 19:119-29.
173. Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006; 38:320-3.
174. Lehman DM, Hunt KJ, Leach RJ, Hamlington J, Arya R, Abboud HE, et al. Haplotypes of Transcription Factor 7-Like 2 (TCF7L2) Gene and Its Upstream Region Are Associated With Type 2 Diabetes and Age of Onset in Mexican Americans. Diabetes 2007; 56:389-93.
175. Scott LJ, Bonnycastle LL, Willer CJ, Sprau AG, Jackson AU, Narisu N, et al. Association of transcription factor 7-like 2 (TCF7L2) variants with type 2 diabetes in a Finnish sample. Diabetes 2006; 55:2649-53.
176. Guo YF, Xiong DH, Shen H, Zhao LJ, Xiao P, Guo Y, et al. Polymorphisms of the lowdensity lipoprotein receptor-related protein 5 (LRP5) gene are associated with obesity phenotypes in a large family-based association study. J Med Genet 2006; 43:798-803.
177. Wright WS, Longo KA, Dolinsky VW, Gerin I, Kang S, Bennett CN, et al. Wnt10b Inhibits Obesity in ob/ ob and Agouti Mice. Diabetes 2007; 56:295-303.
178. Lin CL, Wang JY, Huang YT, Kuo YH, Surendran K, Wang FS. Wnt/beta-catenin signaling modulates survival of high glucose-stressed mesangial cells. J Am Soc Nephrol 2006; 17:2812-20.
179. Kim JR, Jung HS, Bae SW, Kim JH, Park BL, Choi YH, et al. Polymorphisms in FOXO gene family and association analysis with BMI. Obesity (Silver Spring, Md) 2006; 14:188-93.
180. Marchetti V, Menghini R, Rizza S, Vivanti A, Feccia T, Lauro D, et al. Benfotiamine counteracts glucose toxicity effects on endothelial progenitor cell differentiation via Akt/FoxO signaling. Diabetes 2006; 55:2231-7.
181. Fallarino F, Bianchi R, Orabona C, Vacca C, Belladonna ML, Fioretti MC, et al. CTLA-4-Ig activates forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice. J Exp Med 2004; 200:1051-62.
182. Nakae J, Cao Y, Oki M, Orba Y, Sawa H, Kiyonari H, et al. Forkhead transcription factor FoxO1 in adipose tissue regulates energy storage and expenditure. Diabetes 2008; 57:563-76.
183. Puig O, Tjian R. Transcriptional feedback control of insulin receptor by dFOXO/FOXO1. Genes Dev 2005; 19:2435-46.
184. Kamagate A, Dong HH. Foxo1 integrates insulin signaling to VLDL production. Cell Cycle 2008; 7:3162-70.
185. Ni YG, Wang N, Cao DJ, Sachan N, Morris DJ, Gerard RD, et al. FoxO transcription factors activate Akt and attenuate insulin signaling in heart by inhibiting protein phosphatases. Proc Natl Acad Sci USA 2007; 104:20517-22.
186. Kamei Y, Miura S, Suzuki M, Kai Y, Mizukami J, Taniguchi T, et al. Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, downregulated Type I (slow twitch/red muscle) fiber genes, and impaired glycemic control. J Biol Chem 2004; 279:41114-23.
187. Liu CM, Yang Z, Liu CW, Wang R, Tien P, Dale R, et al. Effect of RNA oligonucleotide targeting Foxo-1 on muscle growth in normal and cancer cachexia mice. Cancer Gene Ther 2007; 14:945-52.
188. Sandri M, Lin J, Handschin C, Yang W, Arany ZP, Lecker SH, et al. PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc Natl Acad Sci USA 2006; 103:16260-5.
189. Balan V, Miller GS, Kaplun L, Balan K, Chong ZZ, Li F, et al. Life span extension and neuronal cell protection by Drosophila nicotinamidase. J Biol Chem 2008; 283:27810-9.
190. Chong ZZ, Maiese K. Enhanced Tolerance against Early and Late Apoptotic Oxidative Stress in Mammalian Neurons through Nicotinamidase and Sirtuin Mediated Pathways. Curr Neurovasc Res 2008; 5:159-70.
191. Ma R, Xiong N, Huang C, Tang Q, Hu B, Xiang J, et al. Erythropoietin protects PC12 cells from beta-amyloid(25-35)-induced apoptosis via PI3K/ Akt signaling pathway. Neuropharmacology 2009; 56:1027-34.
192. Sun ZK, Yang HQ, Pan J, Zhen H, Wang ZQ, Chen SD, et al. Protective effects of erythropoietin on tau phosphorylation induced by beta-amyloid. J Neurosci Res 2008; 86:3018-27.
193. Liu R, Suzuki A, Guo Z, Mizuno Y, Urabe T. Intrinsic and extrinsic erythropoietin enhances neuroprotection against ischemia and reperfusion injury in vitro. J Neurochem 2006; 96:1101-10.
194. Meloni BP, Tilbrook PA, Boulos S, Arthur PG, Knuckey NW. Erythropoietin preconditioning in neuronal cultures: signaling, protection from in vitro ischemia, and proteomic analysis. J Neurosci Res 2006; 83:584-93.
195. Wei L, Han BH, Li Y, Keogh CL, Holtzman DM, Yu SP. Cell death mechanism and protective effect of erythropoietin after focal ischemia in the whiskerbarrel cortex of neonatal rats. J Pharmacol Exp Ther 2006; 317:109-16.
196. Yu YP, Xu QQ, Zhang Q, Zhang WP, Zhang LH, Wei EQ. Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia. Neurosci Lett 2005; 387:5-10.
197. Montero M, Poulsen FR, Noraberg J, Kirkeby A, van Beek J, Leist M, et al. Comparison of neuroprotective effects of erythropoietin (EPO) and carbamylerythropoietin (CEPO) against ischemia-like oxygen-glucose deprivation (OGD) and NMDA excitotoxicity in mouse hippocampal slice cultures. Exp Neurol 2007; 204:106-17.
198. Yamasaki M, Mishima HK, Yamashita H, Kashiwagi K, Murata K, Minamoto A, et al. Neuroprotective effects of erythropoietin on glutamate and nitric oxide toxicity in primary cultured retinal ganglion cells. Brain Res 2005; 1050:15-26.
199. Yoo JY, Won YJ, Lee JH, Kim JU, Sung IY, Hwang SJ, et al. Neuroprotective effects of erythropoietin posttreatment against kainate-induced excitotoxicity in mixed spinal cultures. J Neurosci Res 2009; 87:150-63.
200. Bienvenu AL, Ferrandiz J, Kaiser K, Latour C, Picot S. Artesunate-erythropoietin combination for murine cerebral malaria treatment. Acta Trop 2008; 106:104-8.
201. Casals-Pascual C, Idro R, Picot S, Roberts DJ, Newton CR. Can erythropoietin be used to prevent brain damage in cerebral malaria? Trends Parasitol 2009; 25:30-6.
202. Kaiser K, Texier A, Ferrandiz J, Buguet A, Meiller A, Latour C, et al. Recombinant human erythropoietin prevents the death of mice during cerebral malaria. J Infect Dis 2006; 193:987-95.
203. Aoshiba K, Onizawa S, Tsuji T, Nagai A. Therapeutic effects of erythropoietin in murine models of endotoxin shock. Crit Care Med 2009; 37:889-98.
204. Wagner F, Baumgart K, Simkova V, Georgieff M, Radermacher P, Calzia E. Year in review 2007: Critical Care-shock. Crit Care 2008; 12:227.
205. Chen HH, Tarng DC, Lee KF, Wu CY, Chen YC. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease. J Nephrol 2008; 21:543-9.
206. Mao W, Iwai C, Liu J, Sheu SS, Fu M, Liang CS. Darbepoetin alfa exerts a cardioprotective effect in autoimmune cardiomyopathy via reduction of ER stress and activation of the PI3K/Akt and STAT3 pathways. J Mol Cell Cardiol 2008; 45:250-60.
207. Tascilar O, Cakmak GK, Tekin IO, Emre AU, Ucan BH, Bahadir B, et al. Protective effects of erythropoietin against acute lung injury in a rat model of acute necrotizing pancreatitis. World J Gastroenterol 2007; 13:6172-82.
208. Wu H, Dong G, Liu H, Xu B, Li D, Jing H. Erythropoietin attenuates ischemiareperfusion induced lung injury by inhibiting tumor necrosis factor-alpha and matrix metalloproteinase-9 expression. Eur J Pharmacol 2009; 602:406-12.
209. Chen J, Connor KM, Aderman CM, Willett KL, Aspegren OP, Smith LE. Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy. Invest Ophthalmol Vis Sci 2009; 50:1329-35.
210. Wang ZY, Shen LJ, Tu L, Hu DN, Liu GY, Zhou ZL, et al. Erythropoietin protects retinal pigment epithelial cells from oxidative damage. Free Radic Biol Med 2009; 46:1032-41.
211. Zhong Y, Yao H, Deng L, Cheng Y, Zhou X. Promotion of neurite outgrowth and protective effect of erythropoietin on the retinal neurons of rats. Graefes Arch Clin Exp Ophthalmol 2007; 245:1859-67.
212. Zhong YS, Liu XH, Cheng Y, Min YJ. Erythropoietin with retrobulbar administration protects retinal ganglion cells from acute elevated intraocular pressure in rats. J Ocul Pharmacol Ther 2008; 24:453-9.
213. Tsai JC, Song BJ, Wu L, Forbes M. Erythropoietin: a candidate neuroprotective agent in the treatment of glaucoma. J Glaucoma 2007; 16:567-71.
214. King VR, Averill SA, Hewazy D, Priestley JV, Torup L, Michael-Titus AT. Erythropoietin and carbamylated erythropoietin are neuroprotective following spinal cord hemisection in the rat. Eur J Neurosci 2007; 26:90-100.
215. Okutan O, Solaroglu I, Beskonakli E, Taskin Y. Recombinant human erythropoietin decreases myeloperoxidase and caspase-3 activity and improves early functional results after spinal cord injury in rats. J Clin Neurosci 2007; 14:364-8.
216. Verdonck O, Lahrech H, Francony G, Carle O, Farion R, Van de Looij Y, et al. Erythropoietin protects from post-traumatic edema in the rat brain. J Cereb Blood Flow Metab 2007; 27:1369-76.
217. Cherian L, Goodman JC, Robertson C. Neuroprotection with erythropoietin administration following controlled cortical impact injury in rats. J Pharmacol Exp Ther 2007; 322:789-94.
218. Chu K, Jung KH, Lee ST, Kim JH, Kang KM, Kim HK, et al. Erythropoietin reduces epileptogenic processes following status epilepticus. Epilepsia 2008; 49:1723-32.
219. Nadam J, Navarro F, Sanchez P, Moulin C, Georges B, Laglaine A, et al. Neuroprotective effects of erythropoietin in the rat hippocampus after pilocarpineinduced status epilepticus. Neurobiol Dis 2007; 25:412-26.
220. Ferri C, Giuggioli D, Sebastiani M, Colaci M. Treatment of severe scleroderma skin ulcers with recombinant human erythropoietin. Clin Exp Dermatol 2007; 32:287-90.
221. Cuzzocrea S, Mazzon E, di Paola R, Genovese T, Patel NS, Britti D, et al. Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse. Arthritis Rheum 2005; 52:940-50.
222. Wu Y, Shang Y, Sun S, Liang H, Liu R. Erythropoietin prevents PC12 cells from 1-methyl-4-phenylpyridinium ion-induced apoptosis via the Akt/GSK-3beta/ caspase-3 mediated signaling pathway. Apoptosis 2007; 12:1365-75.
223. Li F, Chong ZZ, Maiese K. Erythropoietin on a Tightrope: Balancing Neuronal and Vascular Protection between Intrinsic and Extrinsic Pathways. Neurosignals 2004; 13:265-89.
224. Contaldo C, Meier C, Elsherbiny A, Harder Y, Trentz O, Menger MD, et al. Human recombinant erythropoietin protects the striated muscle microcirculation of the dorsal skinfold from postischemic injury in mice. Am J Physiol Heart Circ Physiol 2007; 293:274-83.
225. Vairano M, Dello Russo C, Pozzoli G, Battaglia A, Scambia G, Tringali G, et al. Erythropoietin exerts anti-apoptotic effects on rat microglial cells in vitro. Eur J Neurosci 2002; 16:584-92.
226. Nakamura T, Sakamoto K. Forkhead transcription factor FOXO subfamily is essential for reactive oxygen species-induced apoptosis. Mol Cell Endocrinol 2007; 281:47-55.
227. Barthelemy C, Henderson CE, Pettmann B. Foxo3a induces motoneuron death through the Fas pathway in cooperation with JNK. BMC Neurosci 2004; 5:48.
228. You H, Yamamoto K, Mak TW. Regulation of transactivation-independent proapoptotic activity of p53 by FOXO3a. Proc Natl Acad Sci USA 2006; 103:9051-6.
229. Won CK, Ji HH, Koh PO. Estradiol prevents the focal cerebral ischemic injury-induced decrease of forkhead transcription factors phosphorylation. Neurosci Lett 2006; 398:39-43.
230. Caporali A, Sala-Newby GB, Meloni M, Graiani G, Pani E, Cristofaro B, et al. Identification of the prosurvival activity of nerve growth factor on cardiac myocytes. Cell Death Differ 2008; 15:299-311.
231. Slotkin TA, Seidler FJ. Protein kinase C is a target for diverse developmental neurotoxicants: transcriptional responses to chlorpyrifos, diazinon, dieldrin and divalent nickel in PC12 cells. Brain Res 2009; 1263:23-32.
232. Slotkin TA, Seidler FJ, Fumagalli F. Targeting of neurotrophic factors, their receptors, and signaling pathways in the developmental neurotoxicity of organophosphates in vivo and in vitro. Brain Res Bull 2008; 76:424-38.
233. Erol A. Unraveling the Molecular Mechanisms Behind the Metabolic Basis of Sporadic Alzheimer's Disease. J Alzheimers Dis 2009.
234. Lu J, Wu DM, Zheng YL, Sun DX, Hu B, Shan Q, et al. Trace amounts of copper exacerbate beta amyloid-induced neurotoxicity in the cholesterol-fed mice through TNF mediated inflammatory pathway. Brain Behav Immun 2009; 23:193-203.
235. Smith WW, Norton DD, Gorospe M, Jiang H, Nemoto S, Holbrook NJ, et al. Phosphorylation of p66Shc and forkhead proteins mediates Abeta toxicity. J Cell Biol 2005; 169:331-9.
236. Mercado-Gomez O, Hernandez-Fonseca K, Villavicencio-Queijeiro A, Massieu L, Chimal-Monroy J, Arias C. Inhibition of Wnt and PI3K signaling modulates GSK-3beta activity and induces morphological changes in cortical neurons: role of tau phosphorylation. Neurochem Res 2008; 33:1599-609.
237. Hoogeboom D, Essers MA, Polderman PE, Voets E, Smits LM, Burgering BM. Interaction of FOXO with {beta}-Catenin Inhibits {beta}-Catenin/T Cell Factor Activity. J Biol Chem 2008; 283:9224-30.
238. Tothova Z, Kollipara R, Huntly BJ, Lee BH, Castrillon DH, Cullen DE, et al. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 2007; 128:325-39.
239. Ferrara N, Rinaldi B, Corbi G, Conti V, Stiuso P, Boccuti S, et al. Exercise Training Promotes SIRT1 Activity in Aged Rats. Rejuvenation Res 2008; 11:139-50.
240. Baoutina A, Alexander IE, Rasko JE, Emslie KR. Potential use of gene transfer in athletic performance enhancement. Mol Ther 2007; 15:1751-66.
241. Diamanti-Kandarakis E, Konstantinopoulos PA, Papailiou J, Kandarakis SA, Andreopoulos A, Sykiotis GP. Erythropoietin abuse and erythropoietin gene doping: detection strategies in the genomic era. Sports Med 2005; 35:831-40.
242. Segura J, Pascual JA, Gutierrez-Gallego R. Procedures for monitoring recombinant erythropoietin and analogues in doping control. Anal Bioanal Chem 2007; 388:1521-9.
243. Frietsch T, Maurer MH, Vogel J, Gassmann M, Kuschinsky W, Waschke KF. Reduced cerebral blood flow but elevated cerebral glucose metabolic rate in erythropoietin overexpressing transgenic mice with excessive erythrocytosis. J Cereb Blood Flow Metab 2007; 27:469-76.
244. Eliopoulos N, Gagnon RF, Francois M, Galipeau J. Erythropoietin delivery by genetically engineered bone marrow stromal cells for correction of anemia in mice with chronic renal failure. J Am Soc Nephrol 2006; 17:1576-84.
245. Orive G, De Castro M, Ponce S, Hernandez RM, Gascon AR, Bosch M, et al. Long-term expression of erythropoietin from myoblasts immobilized in biocompatible and neovascularized microcapsules. Mol Ther 2005; 12:283-9.
246. Ponce S, Orive G, Hernandez RM, Gascon AR, Canals JM, Munoz MT, et al. In vivo evaluation of EPO-secreting cells immobilized in different alginate-PLL microcapsules. J Control Release 2006; 116:28-34.
247. Doolittle ND, Peereboom DM, Christoforidis GA, Hall WA, Palmieri D, Brock PR, et al. Delivery of chemotherapy and antibodies across the blood-brain barrier and the role of chemoprotection, in primary and metastatic brain tumors: report of the Eleventh Annual Blood-Brain Barrier Consortium meeting. J Neurooncol 2007; 81:81-91.
248. Gonzalez FF, McQuillen P, Mu D, Chang Y, Wendland M, Vexler Z, et al. Erythropoietin enhances long-term neuroprotection and neurogenesis in neonatal stroke. Dev Neurosci 2007; 29:321-30.
249. Li Y, Lu Z, Keogh CL, Yu SP, Wei L. Erythropoietininduced neurovascular protection, angiogenesis and cerebral blood flow restoration after focal ischemia in mice. J Cereb Blood Flow Metab 2007; 27:1043-54.
250. Reinders ME, Rabelink TJ, Briscoe DM. Angiogenesis and endothelial cell repair in renal disease and allograft rejection. J Am Soc Nephrol 2006; 17:932-42.
251. Slevin M, Kumar P, Gaffney J, Kumar S, Krupinski J. Can angiogenesis be exploited to improve stroke outcome? Mechanisms and therapeutic potential. Clin Sci 2006; 111:171-83.
252. Zhang SX, Ma JX. Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy. Prog Retin Eye Res 2007; 26:1-37.
253. Hellwinkel OJ, Rogmann JP, Asong LE, Luebke AM, Eichelberg C, Ahyai S, et al. A comprehensive analysis of transcript signatures of the phosphatidylinositol-3 kinase/protein kinase B signal-transduction pathway in prostate cancer. BJU Int 2008; 101:1454-60.
254. Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, Larsson A, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008; 358:2107-16.
255. Hannenhalli S, Putt ME, Gilmore JM, Wang J, Parmacek MS, Epstein JA, et al. Transcriptional genomics associates FOX transcription factors with human heart failure. Circulation 2006; 114:1269-76.